We use cookies on our website. Carry on browsing if you’re happy with this or find out more

Novo Nordisk

Working together since 2013

Novo Nordisk logo 250pxw

Our partnership with Novo Nordisk, Kymab's first, was established in 2013, three years after our formation. 

Kymab granted Novo Nordisk a non-exclusive licence to our proprietary human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK™ and Kymouse HL™ transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates.

Visit the Novo Nordisk website

Our unique platforms can deliver the finest novel therapeutic antibodies

Learn more